Exelixis | EXEL - Current Liabilities


Exelixis reported $411.88M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Akebia Therapeutics USD 162.35M 1.48M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bayer EUR 29.4B 2.87B Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Cytokinetics USD 353.42M 171.99M Sep/2026
Eisai JPY 371.5B 22.14B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Exelixis USD 411.88M 49.95M Sep/2026
Genmab DKK 1.14B 38M Jun/2026
Glaxosmithkline GBP 20.72B 1.71B Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
MacroGenics USD 107.23M 1.58M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Moderna USD 2.03B 506M Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sanofi EUR 31.93B 1.92B Jun/2026
Takeda JPY 2.6T 161B Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Xencor USD 76.27M 5.6M Sep/2026